City Therapeutics Raises $99.5 Million in Series B Funding

City Therapeutics, a Cambridge-based biotech company, has successfully raised $99.5 million in its Series B funding round. This round was led by Viking Global Investors and Sofinnova Investments, with participation from notable investors including Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity Management and Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, and AN Ventures. The funding was announced on June 9, 2026.

Company Background

City Therapeutics is at the forefront of developing innovative therapeutic solutions aimed at addressing unmet medical needs. The company is co-founded by Sebastian Trousil, who serves as the Chief Operating Officer.

Lead Investors

The Series B round was spearheaded by Viking Global Investors and Sofinnova Investments, two prominent names in the investment community. Their involvement underscores the confidence in City Therapeutics’ potential to make significant advancements in the biotech field.

Other Investors

In addition to the lead investors, the round saw participation from a robust lineup of other investors:

  • Casdin Capital
  • NYBC Ventures
  • ARCH Venture Partners
  • Fidelity Management and Research Company
  • Invus
  • Slate Path Capital
  • Rock Springs Capital
  • Regeneron Ventures
  • AN Ventures

Planned Use of Funds

While specific details on the allocation of the new funds were not disclosed, investments of this magnitude typically support the advancement of clinical trials, expansion of research capabilities, and potential scaling of commercial operations. City Therapeutics may utilize this capital to accelerate its pipeline projects and enhance its infrastructure.

Executive Insights

Co-founder and COO Sebastian Trousil commented on the fundraising, highlighting the strategic importance of this investment in bolstering the company's growth trajectory. "This funding round is pivotal for us as we continue to innovate and push the boundaries of what is possible in therapeutic development," Trousil said.

Conclusion

The successful closing of this Series B round places City Therapeutics in a strong position to further its mission. With significant backing from leading investors, the company is expected to make considerable progress in the coming months.